Philippe Laffont
SRNE

Philippe Laffont’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Philippe Laffont’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-750,000
Closed -$5.12M – 96
2020
Q4 		$5.12M Hold
750,000
– – 0.02% 73
2020
Q3 		$8.36M Sell
750,000
-600,000
-44% -$5.49M 0.04% 65
2020
Q2 		$8.48M Buy
+1,350,000
New +$5.17M 0.07% 50

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Philippe Laffont's SRNE Position: Q1 2021 in Review

Philippe Laffont sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2021, closing a stake of 750,000 shares — an estimated $5.12M sold.

Philippe Laffont first reported a position in SRNE in Q2 2020 and held it in 3 quarters. The position peaked at $8.48M in Q2 2020. 231 funds tracked by Wall St. Rank hold SRNE as of Q1 2021.

  • Philippe Laffont reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Philippe Laffont sold 750,000 Sorrento Therapeutics, Inc. shares in Q1 2021, an estimated $5.12M.
  • Philippe Laffont first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
  • Philippe Laffont's Sorrento Therapeutics, Inc. position peaked at $8.48M in Q2 2020.
  • 231 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2021.

Based on Coatue Management's 13F filing for Q1 2021, filed 14 May 2021.